NEWS

Alliance and Natera Announce Activation of Alliance A032103 (MODERN): A Randomized, Phase II/III Adjuvant Trial in Urothelial Cancer

May 1, 2024

First of its kind study in muscle-invasive urothelial cancer, with both escalation and de-escalation arms
Approximately 1,000 patients will be enrolled at more than 300 sites

The Alliance for Clinical Trials in Oncology and Natera, Inc., a global leader in cell-free DNA testing, recently announced the launch of Alliance A032103 (MO


New Trial Alert: Alliance A062102 Multiple Myeloma

April 4, 2024

Alliance A062102: Randomized phase 2 study of iberdomide maintenance therapy following idecaptagene vicleucel CAR-T in multiple myeloma patients

Overview: Alliance investigator Sascha Tuchman, MD, of UNC Lineberger Comprehensive Cancer Center, leads this phase II trial that compares iberdomide maintenance therapy to disease monitoring for improving survival in patients who have received idecabtagene vicleuc


Call for Nominations: Co-Chair, Alliance Publications Committee

January 30, 2024

Konstantin Dragnev, MD, will step down as Co-Chair of the Alliance Publications Committee to transition into his new role as Co-Chair of the Alliance Prevention Committee. Dr. Dragnev, a Professor of Medicine in the Department of Hematology/Oncology at Dartmouth Hitchcock Medical Center, has served in this role since 2015. Alliance wishes to extend our deepest appreciation to Dr. Dragnev for his


Older News